Abstract
Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.
| Original language | English |
|---|---|
| Pages (from-to) | e302-e312 |
| Journal | The Lancet Oncology |
| Volume | 20 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Jun 2019 |
Fingerprint
Cite this
}
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. / Hillengass, Jens; Usmani, Saad; Rajkumar, S. Vincent; Durie, Brian G.M.; Mateos, María Victoria; Lonial, Sagar; Joao, Cristina; Anderson, Kenneth C.; García-Sanz, Ramón; Serra, Eloísa Riva; Du, Juan; van de Donk, Niels; Berdeja, Jesús G.; Terpos, Evangelos; Zamagni, Elena; Kyle, Robert A.; San Miguel, Jesús; Goldschmidt, Hartmut; Giralt, Sergio; Kumar, Shaji; Raje, Noopur; Ludwig, Heinz; Ocio, Enrique; Schots, Rik; Einsele, Hermann; Schjesvold, Fredrik; Chen, Wen Ming; Abildgaard, Niels; Lipe, Brea C.; Dytfeld, Dominik; Wirk, Baldeep Mona; Drake, Matthew; Cavo, Michele; Lahuerta, Juan José; Lentzsch, Suzanne.
In: The Lancet Oncology, Vol. 20, No. 6, 01.06.2019, p. e302-e312.Research output: Contribution to journal › Review article
TY - JOUR
T1 - International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
AU - Hillengass, Jens
AU - Usmani, Saad
AU - Rajkumar, S. Vincent
AU - Durie, Brian G.M.
AU - Mateos, María Victoria
AU - Lonial, Sagar
AU - Joao, Cristina
AU - Anderson, Kenneth C.
AU - García-Sanz, Ramón
AU - Serra, Eloísa Riva
AU - Du, Juan
AU - van de Donk, Niels
AU - Berdeja, Jesús G.
AU - Terpos, Evangelos
AU - Zamagni, Elena
AU - Kyle, Robert A.
AU - San Miguel, Jesús
AU - Goldschmidt, Hartmut
AU - Giralt, Sergio
AU - Kumar, Shaji
AU - Raje, Noopur
AU - Ludwig, Heinz
AU - Ocio, Enrique
AU - Schots, Rik
AU - Einsele, Hermann
AU - Schjesvold, Fredrik
AU - Chen, Wen Ming
AU - Abildgaard, Niels
AU - Lipe, Brea C.
AU - Dytfeld, Dominik
AU - Wirk, Baldeep Mona
AU - Drake, Matthew
AU - Cavo, Michele
AU - Lahuerta, Juan José
AU - Lentzsch, Suzanne
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.
AB - Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.
UR - http://www.scopus.com/inward/record.url?scp=85066247461&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(19)30309-2
DO - 10.1016/S1470-2045(19)30309-2
M3 - Review article
VL - 20
SP - e302-e312
JO - Lancet Oncology
JF - Lancet Oncology
SN - 1470-2045
IS - 6
ER -